Greenwich Lifesciences, Inc. (GLSI) Stock Price & Analysis

Greenwich Lifesciences, Inc. (GLSI) rose 2.05% to USD 15.95 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.

GLSI last closed at USD 15.95; the session ranged USD 15.45–15.98 on volume of 65,124 shares. Market capitalization is —, with a 52-week range of USD 7.78–34.1 (NCM). Source: Nexqual, September 8, 2026 at 07:34 UTC.

Key Statistics (as of September 8, 2026 at 07:34 UTC)

Technical Analysis (GLSI)

Nexqual's technical model rates GLSI "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.

From Greenwich Lifesciences, Inc.'s Latest SEC 10-K Filing (filed 2026-06-01)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, we include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators, and scientific advisors to protect our confidential information and know-how.
• We also rely on trade secrets, know-how, and continuing technological innovation to develop and maintain our proprietary position.   The term of individual patents depends upon the legal term of the patents in countries in which they are obtained.

Partnerships

• HJF may terminate the license if we do not make required payments, if we default in our performance obligations, if we do not sufficiently develop and advance GP2 towards commercialization, and for various other reasons.     In connection with the exclusive license agreement with HJF, we were the financial and corporate sponsors of the GP2 Phase IIb clinical trial.
• Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.   HJF License   Pursuant to our exclusive license agreement with HJF, we were granted exclusive worldwide rights to several U.S. and foreign patents and patent applications covering methods of using GP2.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.